We then estimated whether these 5 FRGs could affect the sensitivity of chemotherapeutic agents commonly used for treating HCC, including sorafenib, gefitinib, paclitaxel, 5-fluorouracil, etoposide, doxorubicin, vinblastine, docetaxel, gemcitabine, cytarabine, AKT inhibitor VIII, sunitinib and metrhotrexate according to the GDSC database using the R package pRRophetic. Here, AKT1 is linked to hepatocellular carcinoma.